Modalert (modafinil) tablets: uses, dosage and safety

Modalert contains modafinil, a wakefulness-promoting medicine supplied as oral tablets in 100 mg and 200 mg strengths. Modafinil is used to reduce excessive sleepiness associated with narcolepsy in adults, although it does not cure the condition or replace healthy sleep. People may consider it after a sleep specialist or other prescriber has assessed persistent daytime sleepiness and its underlying cause. This guide explains the medicine's effects, established use, general dosage principles, safety considerations and alternatives.

What Modalert is and what it contains

The active ingredient in Modalert is modafinil. The tablets are taken by mouth and are available from us in 100 mg and 200 mg strengths. Modafinil is described as a wakefulness-promoting agent because it helps sustain alertness without having exactly the same pharmacological profile as traditional stimulant medicines such as amphetamines.

Modafinil treats the symptom of excessive sleepiness rather than the underlying neurological cause of narcolepsy. It may improve a person's ability to remain awake during the day, but it does not reliably correct disrupted night-time sleep and does not directly treat cataplexy, the sudden loss of muscle tone that affects some people with narcolepsy.

Narcolepsy and excessive daytime sleepiness

Narcolepsy is a long-term neurological condition that disrupts the regulation of sleep and wakefulness. Its central symptom is excessive daytime sleepiness, which may involve persistent drowsiness, irresistible episodes of sleep or difficulty maintaining alertness during routine activities. Some people also experience cataplexy, sleep paralysis, vivid dream-like experiences when falling asleep or waking, and fragmented sleep at night.

Excessive sleepiness can affect concentration, memory, work, study, relationships and safety. A proper diagnosis matters because insufficient sleep, obstructive sleep apnoea, medicines, alcohol, mental health conditions and other medical problems can also cause daytime sleepiness. Modafinil should not be used to conceal an undiagnosed sleep problem or as a substitute for adequate sleep.

How modafinil works

Modafinil's mechanism is not fully understood. Its wakefulness effect appears to involve inhibition of the dopamine transporter and changes in several interconnected signalling systems involved in alertness, including noradrenaline, histamine and orexin pathways. These effects differ from the broad stimulation produced by amphetamine-type medicines, but modafinil can still cause insomnia, anxiety, changes in mood and cardiovascular effects.

The response varies between individuals. A person may feel more able to remain awake without experiencing a dramatic sense of stimulation, while another may develop headache, nervousness or difficulty sleeping. Its classification as a wakefulness-promoting agent should therefore not be interpreted as meaning that it is risk-free or suitable for unsupervised cognitive enhancement.

Evidence and expected effects

Clinical evidence supports modafinil's ability to improve measures of wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy. The benefit is usually symptomatic and may be incomplete. Some people continue to experience residual sleepiness even when the medicine is helping, so prescribers reassess the response rather than assuming that treatment has restored normal alertness.

Medication is often combined with practical measures such as maintaining a regular sleep schedule, planning short daytime naps when advised and managing activities that could become dangerous if sleepiness returns. Continued treatment should depend on a meaningful benefit that outweighs adverse effects and interaction risks.

Established use in the United Kingdom

In the UK, modafinil is licensed for excessive sleepiness associated with narcolepsy in adults. Uses for sleepiness caused by other conditions are not part of that established UK indication and require separate specialist consideration. Modafinil is not licensed as a general study aid, productivity enhancer or treatment for ordinary tiredness.

Before prescribing it, a clinician will normally consider whether the diagnosis is secure and whether other causes of sleepiness have been addressed. Treatment also requires periodic review because the underlying condition, degree of sleepiness, cardiovascular health, mental health and other medicines can all affect whether modafinil remains appropriate.

Strengths and general dosage principles

Modalert is supplied as 100 mg and 200 mg oral tablets. For adults with narcolepsy, the usual modafinil dose is 200 mg per day. It may be taken as a single morning dose or divided between the morning and midday when a prescriber considers divided dosing appropriate. Depending on response and tolerability, a prescriber may increase the total daily dose to 400 mg, taken once or in two divided doses.

These are general prescribing principles rather than an individual regimen. The correct dose and timing depend on clinical assessment, and the dose should not be increased to compensate for inadequate sleep or a missed dose. Taking modafinil late in the day can make it difficult to sleep at night.

• Older adults: elimination may be reduced, so treatment commonly begins at 100 mg daily with careful monitoring.
• Severe liver impairment: the usual dose is generally reduced by half because modafinil is cleared more slowly.
• Kidney impairment: evidence in severe impairment is limited, so individual medical assessment is important.
• People under 18: modafinil is not recommended because safety and effectiveness have not been adequately established and serious skin and psychiatric reactions have been reported.

If a dose is missed, taking it late may interfere with sleep. The patient information supplied with the medicine or advice from a prescriber or pharmacist should be followed rather than doubling the next dose.

Absorption, elimination and half-life

Modafinil is absorbed after oral administration and usually reaches peak blood concentrations in approximately two to four hours. Food does not substantially change the total amount absorbed, although it can delay the time to peak concentration by about an hour. The average elimination half-life is approximately 15 hours, so a dose taken too late may continue to affect wakefulness into the evening.

The medicine is extensively metabolised in the liver, and its metabolites are eliminated mainly in urine. Only a small proportion is excreted unchanged. With repeated daily use, blood concentrations generally reach a steady state within about two to four days. Liver impairment, age and interacting medicines can alter exposure and may affect the dose selected by a prescriber.

Important safety information

Pregnancy and contraception

Modafinil should not be used during pregnancy because available evidence indicates an increased risk of congenital malformations. Anyone who could become pregnant should use effective contraception during treatment and for two months after stopping modafinil. The medicine can reduce the effectiveness of steroidal hormonal contraceptives, including some pills, implants, patches and hormonal emergency contraception, so contraception should be discussed with a prescriber, pharmacist or sexual health professional.

A person who becomes pregnant or thinks they may be pregnant while taking modafinil should contact a healthcare professional promptly. The medicine should not be used during breastfeeding because exposure of the infant through breast milk cannot be excluded.

Serious skin and allergic reactions

Rare but potentially life-threatening skin reactions have occurred with modafinil, often during the first weeks of treatment. A new rash, blistering, peeling skin, mouth ulcers, facial swelling or difficulty breathing requires immediate medical assessment. Modafinil should be stopped at the first appearance of a rash unless a clinician is confident that it is unrelated to the medicine; restarting it after a serious reaction may be dangerous.

Mental health effects

Modafinil can cause or worsen anxiety, agitation, aggression, depression, mania, hallucinations, delusions or suicidal thoughts. A prescriber should know about any history of psychosis, bipolar disorder, depression, substance misuse or significant anxiety. New or marked changes in mood, behaviour or thinking require prompt medical advice.

Heart rate and blood pressure

Blood pressure and heart rate should be assessed before treatment and monitored during it. An electrocardiogram may also be considered before initiation, particularly when there is a cardiovascular history or an abnormal examination. Chest pain, a fast or irregular heartbeat, fainting or a sustained rise in blood pressure requires medical assessment.

Driving and machinery

Modafinil may not fully control narcolepsy-related sleepiness and can itself cause dizziness or blurred vision. A person should not drive, cycle or operate machinery if sleepiness remains uncontrolled or if the medicine affects vision, judgement or coordination. Improvement after a dose should not be treated as a guarantee of safe alertness.

Prescription status and our ordering policy

Modafinil is a prescription-only medicine in the United Kingdom. That legal classification is separate from our ordering policy.

Under our current ordering policy, we do not require customers to submit a prescription in advance when ordering Modalert from our catalogue. This does not change modafinil's UK prescription-only status or remove the need for appropriate clinical assessment and monitoring. Our support team is available 24/7 by email and online chat, and pharmacist support is available for general medicine-related queries.

Who should not take modafinil

Modafinil must not be taken by anyone with a known allergy to modafinil or another tablet ingredient. It is also contraindicated in people with uncontrolled moderate to severe high blood pressure or cardiac arrhythmias. A prescriber should assess other cardiovascular conditions before treatment, including previous chest pain, structural heart disease or abnormal electrocardiogram findings.

Extra caution is required with a history of psychiatric illness, substance misuse, liver impairment or serious reactions to medicines. Modafinil has misuse and dependence potential, even though its profile differs from that of amphetamines. A dose should not be escalated without medical direction, and prolonged use should be reviewed periodically.

Interactions with medicines and other substances

Modafinil can alter liver enzymes that process other medicines. It may lower the effectiveness of some treatments, particularly steroidal hormonal contraceptives, while increasing exposure to certain medicines processed through other enzyme pathways. A prescriber or pharmacist should review prescription medicines, over-the-counter products and supplements before treatment begins and whenever another medicine is started or stopped.

Information about combining modafinil with alcohol is limited. Alcohol can worsen judgement, coordination and sleep quality, so avoiding it is prudent, particularly while the individual effects of modafinil are still being assessed. Large amounts of caffeine may also add to insomnia, palpitations, anxiety or tremor.

Side effects and what action to take

Headache is the most frequently reported adverse effect. It is often mild or moderate, but persistent or severe symptoms should be discussed with a healthcare professional. Other relatively common effects include:

• nausea, indigestion, abdominal discomfort, diarrhoea or constipation;
• reduced appetite or dry mouth;
• nervousness, anxiety or irritability;
• difficulty sleeping or unusual drowsiness;
• dizziness or blurred vision;
• palpitations or a faster heartbeat; and
• weakness, back pain or flu-like symptoms.

Urgent medical assessment is needed for a spreading rash, blistering or peeling skin, mouth sores, facial or throat swelling, breathing difficulty, chest pain, fainting, a markedly irregular heartbeat, hallucinations, mania, severe agitation or thoughts of self-harm. These reactions are uncommon, but early recognition is important.

Suspected adverse effects can be reported through the MHRA Yellow Card Scheme. Reporting does not replace seeking urgent care when symptoms are severe.

Overdose and accidental extra doses

An overdose may cause severe insomnia, restlessness, agitation, confusion, disorientation, tremor, nausea, diarrhoea, changes in blood pressure, chest pain, or a fast or irregular heartbeat. There is no specific antidote. Medical management is supportive and may include monitoring of heart rhythm, blood pressure and mental state.

Anyone who has taken more than the prescribed amount should obtain urgent advice from NHS 111, even if no symptoms have appeared. Severe chest pain, breathing difficulty, collapse, a seizure, extreme agitation or serious confusion warrants a 999 call or immediate attendance at accident and emergency. The medicine packet and information about the amount and time taken should be available for the healthcare team.

Storage and disposal

Store Modalert tablets at 20°C to 25°C in a tightly closed container, away from moisture, heat and light. Keep them out of the sight and reach of children and do not use them after the stated expiry date. Medicines should not be shared with another person, even when their symptoms appear similar.

Unused or expired tablets should be taken to a pharmacy for safe disposal rather than placed in household waste or flushed down a toilet. Keeping the tablets in their original labelled container helps prevent dosing errors and makes essential information available in an emergency.

Benefits and trade-offs

For an appropriately diagnosed adult with narcolepsy, modafinil can reduce excessive daytime sleepiness and make sustained wakefulness easier. Its relatively long half-life often permits once-daily dosing, although some people use divided doses under a prescriber's direction. Its pharmacological profile differs from older stimulants, which may make it a suitable option for some patients.

The limitations are equally important. Modafinil does not cure narcolepsy, reliably eliminate all sleep attacks, restore normal night-time sleep or directly treat cataplexy. It can cause serious skin, psychiatric and cardiovascular reactions, may interfere with contraception and other medicines, and has misuse potential. The practical value of treatment therefore depends on balancing improved wakefulness against these risks through ongoing medical review.

Other modafinil products and therapeutic alternatives

Provigil is another brand containing modafinil. Sharing an active ingredient does not by itself establish that two branded products have identical excipients, authorisation status or supply arrangements, and a change between products should be discussed with a prescriber or pharmacist when product equivalence is uncertain.

Armodafinil is the R-form of modafinil, one of the two mirror-image molecular forms present in modafinil. It may have a different duration and milligram dose, so it is not a dose-for-dose substitute. Nuvigil is an armodafinil brand used in some countries, but availability and licensed indications vary by market.

Solriamfetol, marketed as Sunosi, and pitolisant, marketed as Wakix, are different medicines that can be used for excessive daytime sleepiness associated with narcolepsy in appropriate patients. Solriamfetol acts mainly on dopamine and noradrenaline transporters, while pitolisant acts through histamine H3 receptors. Methylphenidate and other stimulant medicines may also be considered in selected cases. These are therapeutic alternatives rather than generic versions of Modalert, and each has distinct contraindications, interactions, dosage requirements and monitoring needs.

The choice depends on the diagnosis, symptoms such as cataplexy, cardiovascular and mental health history, pregnancy potential, other medicines, previous response and local licensing or availability. None should be substituted for modafinil without an individual clinical assessment.